Nicole Schneiderhan-Marra
STAR LIGHT Study: XBB.1.5 COVID-19 mRNA Vaccines Boost Systemic but Not Mucosal Immunity Against the SARS-CoV-2 JN.1 Variant in Patients with Chronic Liver Disease.
Woelfel S, Junker D, Bergamin I, Meyer-Herbon P, Stillhard R, Graf N, Leinenkugel G, Dütschler J, König M, Häuptle R, Zwyssig S, Krieger-Grübel C, Truniger S, Koller S, Metzger-Peter K, Frei N, Genetics And Observational Subarachnoid Haemorrhage Gosh Study Investigators, Albrich W, Friedrich M, Bernsmeier C, Niess J, Korte W, Bürgi J, Dulovic A, Schneiderhan-Marra N, Semela D, Brand S. STAR LIGHT Study: XBB.1.5 COVID-19 mRNA Vaccines Boost Systemic but Not Mucosal Immunity Against the SARS-CoV-2 JN.1 Variant in Patients with Chronic Liver Disease. Vaccines (Basel) 2024; 12
Oct 31, 2024STAR LIGHT Study: XBB.1.5 COVID-19 mRNA Vaccines Boost Systemic but Not Mucosal Immunity Against the SARS-CoV-2 JN.1 Variant in Patients with Chronic Liver Disease.
Oct 31, 2024Vaccines (Basel) 2024; 12
Woelfel Simon, Junker Daniel, Bergamin Irina, Meyer-Herbon Pamela, Stillhard Roman, Graf Nicole, Leinenkugel Georg, Dütschler Joel, König Marius, Häuptle Rahel, Zwyssig Sarah, Krieger-Grübel Claudia, Truniger Samuel, Koller Seraina, Metzger-Peter Katline, Frei Nicola Fabian, Genetics And Observational Subarachnoid Haemorrhage Gosh Study Investigators, Albrich Werner, Friedrich Matthias, Bernsmeier Christine, Niess Jan-Hendrik, Korte Wolfgang C, Bürgi Justus J, Dulovic Alex, Schneiderhan-Marra Nicole, Semela David, Brand Stephan
XBB.1.5-Adapted COVID-19 mRNA Vaccines but Not Infections With Previous Omicron Variants Boost Neutralisation Against the SARS-CoV-2 JN.1 Variant in Patients With Inflammatory Bowel Disease.
Woelfel S, Dütschler J, Junker D, König M, Graf N, Krieger-Grübel C, Truniger S, Oikonomou V, Leinenkugel G, Koller S, Metzger-Peter K, Wyss J, Krupka N, Frei N, STAR SIGN Study Investigators, Albrich W, Friedrich M, Niess J, Schneiderhan-Marra N, Dulovic A, Misselwitz B, Korte W, Bürgi J, Brand S. XBB.1.5-Adapted COVID-19 mRNA Vaccines but Not Infections With Previous Omicron Variants Boost Neutralisation Against the SARS-CoV-2 JN.1 Variant in Patients With Inflammatory Bowel Disease. Aliment Pharmacol Ther 2024
Oct 29, 2024XBB.1.5-Adapted COVID-19 mRNA Vaccines but Not Infections With Previous Omicron Variants Boost Neutralisation Against the SARS-CoV-2 JN.1 Variant in Patients With Inflammatory Bowel Disease.
Oct 29, 2024Aliment Pharmacol Ther 2024
Woelfel Simon, Dütschler Joel, Junker Daniel, König Marius, Graf Nicole, Krieger-Grübel Claudia, Truniger Samuel, Oikonomou Vasileios, Leinenkugel Georg, Koller Seraina, Metzger-Peter Katline, Wyss Jacqueline, Krupka Niklas, Frei Nicola Fabian, STAR SIGN Study Investigators, Albrich Werner, Friedrich Matthias, Niess Jan-Hendrik, Schneiderhan-Marra Nicole, Dulovic Alex, Misselwitz Benjamin, Korte Wolfgang C, Bürgi Justus J, Brand Stephan
Systemic and Mucosal Immunogenicity of Monovalent XBB.1.5-Adapted COVID-19 mRNA Vaccines in Patients with Inflammatory Bowel Disease.
Woelfel S, Dütschler J, Junker D, König M, Leinenkugel G, Graf N, Krieger-Grübel C, Truniger S, Franke A, Koller S, Metzger-Peter K, Oberholzer M, Frei N, Geissler N, Schaub P, Genetics And Observational Subarachnoid Haemorrhage Gosh Study Investigators, Albrich W, Friedrich M, Niess J, Schneiderhan-Marra N, Dulovic A, Korte W, Bürgi J, Brand S. Systemic and Mucosal Immunogenicity of Monovalent XBB.1.5-Adapted COVID-19 mRNA Vaccines in Patients with Inflammatory Bowel Disease. Vaccines (Basel) 2024; 12
Jul 15, 2024Systemic and Mucosal Immunogenicity of Monovalent XBB.1.5-Adapted COVID-19 mRNA Vaccines in Patients with Inflammatory Bowel Disease.
Jul 15, 2024Vaccines (Basel) 2024; 12
Woelfel Simon, Dütschler Joel, Junker Daniel, König Marius, Leinenkugel Georg, Graf Nicole, Krieger-Grübel Claudia, Truniger Samuel, Franke Annett, Koller Seraina, Metzger-Peter Katline, Oberholzer Melanie, Frei Nicola Fabian, Geissler Nora, Schaub Peter, Genetics And Observational Subarachnoid Haemorrhage Gosh Study Investigators, Albrich Werner, Friedrich Matthias, Niess Jan-Hendrik, Schneiderhan-Marra Nicole, Dulovic Alex, Korte Wolfgang C, Bürgi Justus J, Brand Stephan
STAR SIGN study: Evaluation of COVID-19 vaccine efficacy against the SARS-CoV-2 variants BQ.1.1 and XBB.1.5 in patients with inflammatory bowel disease.
Woelfel S, Dütschler J, König M, Dulovic A, Graf N, Junker D, Oikonomou V, Krieger-Grübel C, Truniger S, Franke A, Eckhold A, Forsch K, Koller S, Wyss J, Krupka N, Oberholzer M, Frei N, Geissler N, Schaub P, STAR SIGN Study Investigators, Albrich W, Friedrich M, Schneiderhan-Marra N, Misselwitz B, Korte W, Bürgi J, Brand S. STAR SIGN study: Evaluation of COVID-19 vaccine efficacy against the SARS-CoV-2 variants BQ.1.1 and XBB.1.5 in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2023; 58:678-691.
Aug 12, 2023STAR SIGN study: Evaluation of COVID-19 vaccine efficacy against the SARS-CoV-2 variants BQ.1.1 and XBB.1.5 in patients with inflammatory bowel disease.
Aug 12, 2023Aliment Pharmacol Ther 2023; 58:678-691
Woelfel Simon, Dütschler Joel, König Marius, Dulovic Alex, Graf Nicole, Junker Daniel, Oikonomou Vasileios, Krieger-Grübel Claudia, Truniger Samuel, Franke Annett, Eckhold Annika, Forsch Kristina, Koller Seraina, Wyss Jacqueline, Krupka Niklas, Oberholzer Melanie, Frei Nicola Fabian, Geissler Nora, Schaub Peter, STAR SIGN Study Investigators, Albrich Werner, Friedrich Matthias, Schneiderhan-Marra Nicole, Misselwitz Benjamin, Korte Wolfgang C, Bürgi Justus J, Brand Stephan
Pulmonary Surfactant Proteins Are Inhibited by Immunoglobulin A Autoantibodies in Severe COVID-19.
Sinnberg T, Lichtensteiger C, Ali O, Pop O, Risch L, Brugger S, Velic A, Bomze D, Kohler P, Vernazza P, Albrich W, Kahlert C, Abdou M, Wyss N, Hofmeister K, Niessner H, Zinner C, Gilardi M, Tzankov A, Röcken M, Dulovic A, Shambat S, Ruetalo N, Buehler P, Scheier T, Jochum W, Kern L, Henz S, Schneider T, Kuster G, Lampart M, Siegemund M, Bingisser R, Schindler M, Schneiderhan-Marra N, Kalbacher H, McCoy K, Spengler W, Brutsche M, Macek B, Twerenbold R, Penninger J, Matter M, Flatz L, Jochum A. Pulmonary Surfactant Proteins Are Inhibited by Immunoglobulin A Autoantibodies in Severe COVID-19. Am J Respir Crit Care Med 2023; 207:38-49.
Jan 1, 2023Pulmonary Surfactant Proteins Are Inhibited by Immunoglobulin A Autoantibodies in Severe COVID-19.
Jan 1, 2023Am J Respir Crit Care Med 2023; 207:38-49
Sinnberg Tobias, Lichtensteiger Christa, Ali Omar Hasan, Pop Oltin T, Risch Lorenz, Brugger Silvio D, Velic Ana, Bomze David, Kohler Philipp, Vernazza Pietro, Albrich Werner, Kahlert Christian, Abdou Marie-Therese, Wyss Nina, Hofmeister Kathrin, Niessner Heike, Zinner Carl, Gilardi Mara, Tzankov Alexandar, Röcken Martin, Dulovic Alex, Shambat Srikanth Mairpady, Ruetalo Natalia, Buehler Philipp K, Scheier Thomas C, Jochum Wolfram, Kern Lukas, Henz Samuel, Schneider Tino, Kuster Gabriela M, Lampart Maurin, Siegemund Martin, Bingisser Roland, Schindler Michael, Schneiderhan-Marra Nicole, Kalbacher Hubert, McCoy Kathy D, Spengler Werner, Brutsche Martin H, Macek Boris, Twerenbold Raphael, Penninger Josef M, Matter Matthias S, Flatz Lukas, Jochum Ann-Kristin
A frequent hypofunctional IRAK2 variant is associated with reduced spontaneous hepatitis C virus clearance
Wang H, Pichulik T, Mullhaupt B, Semela D, Dufour J, Bochud P, Bowie A, Kalinke U, Berg T, Weber A, Wiese M, Löffler M, El Maadidi S, Fischer J, Grabski E, Dickhöfer S, Klimosch S, Flannery S, Filomena A, Wolz O, Schneiderhan-Marra N, East-German and Swiss Hepatitis C Virus Study Groups. A frequent hypofunctional IRAK2 variant is associated with reduced spontaneous hepatitis C virus clearance. Hepatology 2015; 62:1375-87.
Sep 28, 2015A frequent hypofunctional IRAK2 variant is associated with reduced spontaneous hepatitis C virus clearance
Sep 28, 2015Hepatology 2015; 62:1375-87
Wang Hui, Pichulik Tica, Mullhaupt Beat, Semela David, Dufour Jean-François, Bochud Pierre-Yves, Bowie Andrew G, Kalinke Ulrich, Berg Thomas, Weber Alexander N R, Wiese Manfred, Löffler Markus W, El Maadidi Souhayla, Fischer Janett, Grabski Elena, Dickhöfer Sabine, Klimosch Sascha, Flannery Sinead M, Filomena Angela, Wolz Olaf-Oliver, Schneiderhan-Marra Nicole, East-German and Swiss Hepatitis C Virus Study Groups